A Pivotal Legal Battle Looms for Bayer in Washington

Bayer faces a pivotal US Supreme Court hearing on glyphosate lawsuits in April 2026. A favorable ruling could slash its massive legal liability, while a negative one jeopardizes its $7.25B settlement plan.

The German pharmaceutical and agricultural giant Bayer faces a critical juncture in its ongoing US legal saga. The company's most significant historical liability hinges on a Supreme Court hearing scheduled for late April, which will examine the validity of tens of thousands of lawsuits linked to the herbicide glyphosate. A favorable ruling could dramatically reduce this massive legal overhang, whereas an unfavorable decision would undermine the company's current settlement strategy.

Financial and Operational Strain Persists

The long shadow of litigation continues to impact Bayer's financial results. For the 2025 fiscal year, the Leverkusen-based group reported an EBITDA of approximately €9.7 billion, meeting its operational targets. However, this was overshadowed by a net loss of €3.6 billion. Management has further cautioned that substantial settlement payments will likely result in a deeply negative free cash flow for the current year.

This challenging outlook is reflected in the market's recent assessment of the stock. Shares closed at €37.65 on Friday, marking a monthly decline exceeding 13 percent. With a Relative Strength Index (RSI) reading of 16.5, the equity is technically considered to be in severely oversold territory.

The Dual-Pronged Legal Strategy

At the heart of the matter is the legal principle of federal preemption. On April 27, 2026, the US Supreme Court will hear arguments on whether the Environmental Protection Agency's (EPA) approval of the weedkiller Roundup preempts state-level lawsuits alleging a failure to provide cancer warnings. A ruling in Bayer's favor would effectively remove the legal foundation for roughly 65,000 pending claims.

Concurrently, a separate damage-control effort is underway. A US judge has granted preliminary approval to a settlement proposal valued at $7.25 billion. This financial framework, however, is contingent upon near-total participation from plaintiffs. Should the Supreme Court rule against the company, analysts suggest the negotiated sum would likely prove insufficient to cover future legal liabilities. To date, Bayer has paid over $11 billion in settlements and penalties since its acquisition of Monsanto.

Shareholder Meeting Precedes Court Date

Before attention shifts to Washington, Bayer will hold its virtual Annual General Meeting on April 24. The board is expected to present a mixed operational picture, particularly within its agricultural division:

• Corn Business: Achieved global sales growth of 13.2 percent in 2025.
• Soybeans and Cotton: Recorded significant sales declines in the US market, primarily due to the revocation of dicamba product labels.
• Dividend: A minimum dividend of €0.11 per share is proposed, with an ex-dividend date of April 27.

A final resolution on the US legal front is anticipated before the Supreme Court's current session concludes in June 2026. Until that decision is rendered, the company's fundamental business performance is likely to remain secondary to legal developments in the eyes of many investors.